RaySearch and IBA expand their partnership in proton therapy
Retrieved on:
Tuesday, October 26, 2021
Proton, RaySearch Laboratories, Research, Radiation, Nasdaq Stockholm, Conformal, Cancer, Bragg peak, OAS, Carbon, Workflow, Steve, Partnership, Patient, Radiopharmaceutical, Photon, HDR, ARC, OIS, Ion, Software, FLASH, Ion Beam Applications, Proton therapy, CEO, Helium, TCS, Sterilization, Proteus, Bloomberg, IBA, Electron, Health, Reuters, B Corporation (certification), Medical imaging
STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.
Key Points:
- STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.
- RaySearch and IBA have had a strategic partnership on a global level since 2013.
- The result will be a turnkey solution for all software and hardware needed to deliver outstanding proton therapy treatments.
- Johan Lf, founder and CEO, RaySearch, says: "Today the combination of RaySearch's RayStation and IBA's Proteus is an industry standard within proton therapy.